Skip to main content

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Concepció Jacobs Cachá

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Red de investigación Renal

IP: Daniel Serón Micas
Collaborators: Joan López Hellin, Red de investigación Renal, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, Joana Sellarés Roig, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 92250
Reference: RD12/0021/0013
Duration: 01/01/2013 - 31/12/2016

Kidney and sex hormones: Novel insights into development and progression of the metabolic syndrome

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Concepció Jacobs Cachá, Andrea Caballero Garralda
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 266200
Reference: SAF2011-29506
Duration: 01/01/2012 - 31/12/2014

Ministerio de Ciencia

Acción andrógénica y función renal: Implicación de la Kidney androgen-regulated protein (KAP)

IP: Anna Meseguer Navarro
Collaborators: Joan López Hellin, Maria Teresa Salcedo Allende, Concepció Jacobs Cachá
Funding agency: Sociedad Española de Nefrología (S.E.N.)
Funding: 18000
Reference: SENEFRO/01/08
Duration: 01/02/2009 - 31/01/2011

Patologia Cel·lular

IP: Patologia Cel·lular
Collaborators: Joan López Hellin, Ramón Vilalta Casas, Alvaro Domingo Madrid Aris, Francesc Moreso Mateos, Enric Trilla Herrera, Daniel Serón Micas, Luis Enrique Lara Moctezuma, Concepció Jacobs Cachá, Carles Xavier Raventós Busquets
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2009 SGR 75
Duration: 01/01/2010 - 30/04/2014

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

Andrea Sallent Font

Andrea Sallent Font

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Bernat López Masramon

Bernat López Masramon

Predoctoral researcher
Donation and transplantation of organs, tissues and cells
Read more
Bernat Massó Carreras

Bernat Massó Carreras

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Giuliana Rios Quiñones

Giuliana Rios Quiñones

Research technician
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.